KTRA — Kintara Therapeutics Income Statement
0.000.00%
- $13.94m
- $17.84m
Annual income statement for Kintara Therapeutics, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.4 | 9.2 | 38.2 | 22.7 | 14.8 |
Operating Profit | -8.4 | -9.2 | -38.2 | -22.7 | -14.8 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.05 | -9.13 | -38.3 | -22.7 | -14.6 |
Net Income After Taxes | -8.05 | -9.13 | -38.3 | -22.7 | -14.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.05 | -9.13 | -38.3 | -22.7 | -14.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.13 | -9.13 | -41.5 | -25.1 | -15 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -158 | -38.7 | -79.2 | -25.8 | -9.27 |